SEC Filing Summary: RXi Pharmaceuticals Corporation (8-K)
Business Context and Reporting Period
This Form 8-K was filed by RXi Pharmaceuticals Corporation (not SELLAS Life Sciences Group, Inc.) on March 31, 2010. The report serves to announce the financial results for the fourth quarter and the full fiscal year ended December 31, 2009. The detailed results are contained in a press release attached as Exhibit 99.1.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are referenced as being included in the attached press release (Exhibit 99.1) but are not present in the body of this 8-K document.
Material Changes
No specific material changes versus prior periods are detailed in the text of this filing. The document solely acts as a notification that the results for the period ended December 31, 2009, have been issued.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information furnished under Item 2.02 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liability of such section. No specific guidance, outlook, or risk factors are detailed in the text of this 8-K.
Investor Verification Checklist
- Verify the correct registrant name: RXi Pharmaceuticals Corporation (distinct from SELLAS Life Sciences Group, Inc.).
- Review Exhibit 99.1 (Press Release) for actual financial figures, as they are not listed in the 8-K text.
- Confirm the fiscal year-end date of December 31, 2009, for the reported results.
- Note that the information in this 8-K is not incorporated by reference into other filings unless expressly stated.